Cost-Effectiveness of CT Perfusion for Selecting Patients for Intravenous Thrombolysis: A US Hospital Perspective

References

1. 1.↵
   1. Adams HP Jr.,
   2. del Zoppo G,
   3. Alberts MJ,
   4. et al.

   , for the American Heart Association, American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups—the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38: 1655– 711

   Abstract/FREE Full Text
2. 2.↵
   Intercollegiate Stroke Working Party. National Clinical Guidelines for Stroke. London: Royal College of Physicians; 2004
3. 3.↵
   1. Thomalla G,
   2. Schwark C,
   3. Sobesky J,
   4. et al

   . Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke 2006; 37: 852– 58

   Abstract/FREE Full Text
4. 4.↵
   1. Schellinger PD,
   2. Thomalla G,
   3. Fiehler J,
   4. et al

   . MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients. Stroke 2007; 38: 2640– 45

   Abstract/FREE Full Text
5. 5.↵
   1. Wintermark M,
   2. Flanders AE,
   3. Velthuis B,
   4. et al

   . Perfusion-CT assessment of infarct core and penumbra receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke 2006; 37: 979– 85

   Abstract/FREE Full Text
6. 6.↵
   1. Hacke W,
   2. Kaste M,
   3. Bluhmki E,
   4. et al.

   , for the ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317– 29

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Earnshaw SR,
   2. Jackson D,
   3. Farkouh R,
   4. et al

   . Cost-effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis. Stroke 2009; 40: 1710– 20

   Abstract/FREE Full Text
8. 8.↵
   1. Hacke W,
   2. Donnan G,
   3. Fieschi C,
   4. et al.

   , and the ATLANTIS Trials Investigators, ECASS Trials Investigators, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768– 74

   CrossRefPubMedWeb of Science
9. 9.↵
   Activase (alteplase) [package insert]. San Francisco, California: Genentech; 2005
10. 10.↵
    1. Katzan IL,
    2. Hammer MD,
    3. Hixson ED,
    4. et al

    . Cleveland Clinic Health System Stroke Quality Improvement Team: utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004; 61: 346– 50

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Schellinger PD,
    2. Fiebach JB,
    3. Hacke W

    . Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke 2003; 34: 575– 83

    Abstract/FREE Full Text
12. 12.↵
    1. Darby DG,
    2. Barber PA,
    3. Gerraty RP,
    4. et al

    . Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI. Stroke 1999; 30: 2043– 52

    Abstract/FREE Full Text
13. 13.↵
    1. Morris DL,
    2. Rosamond W,
    3. Madden K,
    4. et al

    . Prehospital and emergency department delays after acute stroke: the Genentech Stroke Presentation Survey. Stroke 2000; 31: 2585– 90

    Abstract/FREE Full Text
14. 14.↵
    1. Smith RW,
    2. Scott PA,
    3. Grant RJ,
    4. et al

    . Emergency physician treatment of acute stroke with recombinant tissue plasminogen activator: a retrospective analysis. Acad Emerg Med 1999; 6: 618– 25

    PubMedWeb of Science
15. 15.↵
    Medical Consumer Price Index. 2008. http://data.bls.gov/PDQ/outside.jsp?survey=cu. Accessed June 30, 2008
16. 16.↵
    1. Gold MR,
    2. Siegel JE,
    3. Russell LB,
    4. et al

    . Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996
17. 17.↵
    1. Earnshaw SR,
    2. Joshi AV,
    3. Wilson MR,
    4. et al

    . Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke 2006; 37: 2751– 58

    Abstract/FREE Full Text
18. 18.↵
    1. Arias E

    . United States life tables, 2003. Natl Vital Stat Rep 2006; 54: 1– 40

    PubMed
19. 19.↵
    1. Samsa GP,
    2. Reutter RA,
    3. Parmigiani G,
    4. et al

    . Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J Clin Epidemiol 1999; 52: 259– 71

    CrossRefPubMedWeb of Science
20. 20.
    1. Lloyd-Jones D,
    2. Adams R,
    3. Carnethon M,
    4. et al.

    , for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2009 update—a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: 480– 86

    FREE Full Text
21. 21.
    Nationwide Inpatient Sample. Healthcare Cost and Utilization Project. 2000–2001. http://www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed May 20, 2009
22. 22.
    1. Fagan SC,
    2. Morgenstern LB,
    3. Petitta A,
    4. et al

    . Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke: NINDS rtPA Stroke Study Group. Neurology 1996; 50: 883– 90
23. 23.
    1. Aspelin P,
    2. Aubry P,
    3. Fransson SG,
    4. et al

    . Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy. Am Heart J 2005; 149: 298– 303

    CrossRefPubMedWeb of Science
24. 24.
    1. Gleeson TG,
    2. Bulugahapitiya S

    . Contrast-induced nephropathy. AJR Am J Roentgenol 2005; 185: 1079
25. 25.
    1. Shield CF,
    2. Jacobs RJ,
    3. Wyant S

    . A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation. Am J Kidney Dis 1996; 28: 958
26. 26.
    1. Beebe A,
    2. Dalton JA,
    3. Espronceda M

    . CPT 2009 Standard Edition. Chicago: American Medical Association; 2009
27. 27.
    Ingenix. The Essential Resource-Based Relative Value Scale: A Comprehensive Listing of RBRVS Values for CPT and HCPCS Codes. Eden Prairie, Minnesota: St. Anthony Publishing; 2008
28. 28.
    Red Book for Windows [computer program]. Version 61127, Volume 41. Montvale, New Jersey: Thomson PDR; 2006
29. 29.↵
    1. Earnshaw SR,
    2. Wilson M,
    3. Mauskopf J,
    4. et al

    . Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges. Value Health 2009; 12: 507– 20. Epub 2008 Nov 10

    CrossRefPubMed